Brief: Axovant Enters Into Sales Agreement With SVB Leerink LLC
April 29 (Reuters) - Axovant Gene Therapies Ltd AXGT.O :
* AXOVANT GENE THERAPIES LTD - ENTERED INTO A SALES
AGREEMENT WITH
SVB LEERINK LLC, TO SELL COMMON SHARES HAVING OFFERING PRICE OF
UP TO $25 MILLION
Source text: (https://bit.ly/2yR4nsu)
Further company coverage: AXGT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sio Gene Therapies
See all newsBrief: Sio Gene Therapies Inc - On March 14, Got Notice That Nasdaq Has Determined That Company's Common Stock Will Be Delisted From Nasdaq Capital Market
Brief: Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
Brief: Sio Gene Therapies Inc. Announces Board Approval Of Plan Of Complete Liquidation, Dissolution
Brief: Sio Gene Therapies Announces Second Quarter Financial Results
Brief: Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results